Results 151 to 160 of about 2,631,955 (205)

Pembrolizumab efficacy in a tumor mutation burden-high glioblastoma patient: A case study and implications for precision oncology. [PDF]

Cancer Sci
Nishiyama A, Sato S, Sakaguchi H, Kotani H, Yamashita K, Ohtsubo K, Sekiya T, Watanabe A, Tajima A, Shimaguchi C, Mizuguchi K, Ikeda H, Kinoshita M, Nakada M, Takeuchi S.   +14 more
europepmc   +1 more source

Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer. [PDF]

Ger Med Sci
Kumari B, Lahariya R.
europepmc   +1 more source

Prognostic implications of ERLncRNAs in ccRCC: a novel risk score model and its association with tumor mutation burden and immune microenvironment. [PDF]

Discov Oncol
Feng K, Li J, Li J, Li Z, Li Y.
europepmc   +1 more source

Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and <i>BRAF V600</i> mutation. [PDF]

Front Oncol
Forschner J, Huynh J, Schroeder C, Armeanu-Ebinger S, Seibel-Kelemen O, Gschwind A, Bonzheim I, Eigentler TK, Amaral T, Ossowski S, Flatz L, Garbe C, Forschner A, Reitmajer M.   +13 more
europepmc   +1 more source

FAT4 Mutation is Related to Tumor Mutation Burden and Favorable Prognosis in Gastric Cancer. [PDF]

Curr Genomics
Li Q, Chu Y, Yao Y, Song Q.
europepmc   +1 more source

A Case of Advanced Extramammary Paget's Disease With a High Tumor Mutation Burden That Showed Partial Lymph Node Regression With Pembrolizumab. [PDF]

Cureus
Horisaki K, Taki T, Mori S, Okumura M, Akiyama M.   +4 more
europepmc   +1 more source

Long-Term Complete Response to Pembrolizumab in Tumor Mutation Burden-High Small Cell Lung Cancer: A Case Report. [PDF]

Case Rep Oncol
Komuta K, Kunimasa K, Miyazaki A, Futamura S, Tanaka T, Kawamura T, Inoue T, Tamiya M, Nishino K.   +8 more
europepmc   +1 more source

Construction of a novel tumor mutation burden-related mRNA signature for prognosis prediction in laryngeal squamous cell carcinoma. [PDF]

Medicine (Baltimore)
Jiang WJ, Wang C, Hu ZH, Jiang XZ, Hu WM.   +4 more
europepmc   +1 more source

Of Context, Quality, and Complexity: Fine-Combing Tumor Mutational Burden in Immunotherapy-Treated Cancers. [PDF]

Clin Cancer Res
Niknafs N, Najjar M, Dennehy C, Stouras I, Anagnostou V.   +4 more
europepmc   +1 more source

Predicting tumor mutation burden and VHL mutation from renal cancer pathology slides with self-supervised deep learning. [PDF]

Cancer Med
Zheng Q, Wang X, Yang R, Fan J, Yuan J, Liu X, Wang L, Xiao Z, Chen Z.   +8 more
europepmc   +1 more source